Dehydrocostuslactone
CAS No. 74299-48-2
Dehydrocostuslactone( —— )
Catalog No. M24751 CAS No. 74299-48-2
Dehydrocostuslactone is a natural product extracted from Aucklandia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 92 | In Stock |
|
| 5MG | 106 | In Stock |
|
| 10MG | 150 | In Stock |
|
| 25MG | 275 | In Stock |
|
| 50MG | 405 | In Stock |
|
| 100MG | 607 | In Stock |
|
| 200MG | 851 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDehydrocostuslactone
-
NoteResearch use only, not for human use.
-
Brief DescriptionDehydrocostuslactone is a natural product extracted from Aucklandia.
-
DescriptionDehydrocostuslactone is a natural product extracted from Aucklandia.It has wide spectrum of biological effects, including anti-inflammatory, anticancer, antiviral, antimicrobial, antifungal, antioxidant, antidiabetic, antiulcer, and anthelmintic activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number74299-48-2
-
Formula Weight230.3
-
Molecular FormulaC15H18O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC=C1CCC2C(C3C1CCC3=C)OC(=O)C2=C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Norswertianolin
Norswertianolin, a compound isolated from G. acuta, functions as a CSE activator and shows promise as a potential cardiovascular therapeutic.
-
Succinyl-(Pro58,D-Gl...
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM.
-
Elezanumab
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.
Cart
sales@molnova.com